Johannes Fischer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Johannes Fischer has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Aleksandar Radujkovic
Department of Hematology, Oncology and Clinical Immunology, Medical Faculty, University Hospital Düsseldorf, Heinrich-Heine-University Düsseldorf, D-40225 Düsseldorf, Germany
1 shared publication - Ben-Niklas Baermann
Department of Hematology, Oncology and Clinical Immunology, Medical Faculty, University Hospital Düsseldorf, Heinrich-Heine-University Düsseldorf, D-40225 Düsseldorf, Germany
1 shared publication - Christina Antke
Department of Nuclear Medicine, Medical Faculty and University Hospital Duesseldorf, Heinrich-Heine-University Duesseldorf, 40225 Düsseldorf, Germany
1 shared publication - Daniel Weiss
Department of Diagnostic and Interventional Radiology, Medical Faculty and University Hospital Düsseldorf, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany
1 shared publication - Eduards Mamlins
Department of Nuclear Medicine, Medical Faculty and University Hospital Duesseldorf, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany
1 shared publication - Emil Novruzov
Department of Nuclear Medicine, Medical Faculty and University Hospital Duesseldorf, Heinrich-Heine-University Duesseldorf, Düsseldorf, Germany
1 shared publication
Latest Publications
- Open Access
- 13 August 2025
- Published by MDPI AG in Diagnostics
- Vol. 15 (16) , 2025
Predictive Power of Baseline [18F]FDG PET/CT for Adverse Events in DLBCL Patients Undergoing CAR-T Cell Therapy
Objectives: Evaluation of the predictive potential of pre-CAR-T [18F]FDG PET/CT in Diffuse Large B-Cell Lymphoma (DLBCL) patients concerning Cytokine Release Syndrome (CRS) and Immune Effector Cell-associated Neurotoxicity Syndrome (ICANS). Methods: Eighteen DLBCL patients (mean age: 60 ± 12 years) who underwent pre-therapeutic [18F]FDG-PET/CT and CAR-T cell therapy were retrospectively included. Median follow-up time was ten months (IQR6-16) after CAR-T cell infusion. Age, sex, serum lactate dehydrogenase (LDH), interleukin-6 (IL-6), C-reactive protein (CRP), and modified Endothelial Activation and Stress Index (mEASIX) were obtained. Potential occurrence of CRS/ICANS and the SUVmax were evaluated. Pearson and Spearman correlations, group comparisons (Mann–Whitney U-test) and the odds ratio (OR) were calculated. P values below 0.05 were defined as statistically significant and 95%-confidence intervals (CI) were calculated. Results: Pre-therapeutic SUVmax correlated positively with LDH (r = 0.5; p = 0.02), with the grade of CRS (r = 0.5; p = 0.03) and with the grade of ICANS (r = 0.6; p = 0.01). Appearance of ICANS was significantly correlated with pre-therapeutic SUVmax (p = 0.03; U = 7.0; Z = −2.2). Using ROC analysis and Youden’s index, an SUVmax threshold of 17 (AUC: 0.865; p < 0.01) was defined. Patients exceeding a pre-therapeutic SUVmax of 17 had a significantly higher risk of CRS grade > 1 (OR = 22; CI 2, 314; p = 0.03) and ICANS grade > 1 (OR = 18; CI 1, 271; p = 0.04). Conclusions: Pre-therapeutic SUVmax may be a useful marker for identifying DLBCL patients at risk for CRS and ICANS.
- 13 August 2025
- Published by MDPI AG in Diagnostics
- Vol. 15 (16) , 2025
Open AccessPredictive Power of Baseline [18F]FDG PET/CT for Adverse Events in DLBCL Patients Undergoing CAR-T Cell Therapy
Objectives: Evaluation of the predictive potential of pre-CAR-T [18F]FDG PET/CT in Diffuse Large B-Cell Lymphoma (DLBCL) patients concerning Cytokine Release Syndrome (CRS) and Immune Effector Cell-associated Neurotoxicity Syndrome (ICANS). Methods: Eighteen DLBCL patients (mean age: 60 ± 12 years) who underwent pre-therapeutic [18F]FDG-PET/CT and CAR-T cell therapy were retrospectively included. Median follow-up time was ten months (IQR6-16) after CAR-T cell infusion. Age, sex, serum lactate dehydrogenase (LDH), interleukin-6 (IL-6), C-reactive protein (CRP), and modified Endothelial Activation and Stress Index (mEASIX) were obtained. Potential occurrence of CRS/ICANS and the SUVmax were evaluated. Pearson and Spearman correlations, group comparisons (Mann–Whitney U-test) and the odds ratio (OR) were calculated. P values below 0.05 were defined as statistically significant and 95%-confidence intervals (CI) were calculated. Results: Pre-therapeutic SUVmax correlated positively with LDH (r = 0.5; p = 0.02), with the grade of CRS (r = 0.5; p = 0.03) and with the grade of ICANS (r = 0.6; p = 0.01). Appearance of ICANS was significantly correlated with pre-therapeutic SUVmax (p = 0.03; U = 7.0; Z = −2.2). Using ROC analysis and Youden’s index, an SUVmax threshold of 17 (AUC: 0.865; p < 0.01) was defined. Patients exceeding a pre-therapeutic SUVmax of 17 had a significantly higher risk of CRS grade > 1 (OR = 22; CI 2, 314; p = 0.03) and ICANS grade > 1 (OR = 18; CI 1, 271; p = 0.04). Conclusions: Pre-therapeutic SUVmax may be a useful marker for identifying DLBCL patients at risk for CRS and ICANS.